|
|
||||||||
From the Walter Reed Army Institute of Research, Washington, D. C., and the Department of Medicine, School of Medicine, University of Maryland, Baltimore 1, Maryland
Abstract
Lyophilization of formalin-inactivated Rift Valley fever virus vaccine, prepared in African green monkey kidney cell cultures, was successfully accomplished by the addition of 2% U.S.P. human serum albumin (HSA). The choice of HSA as an additive was made because it is non-allergenic for man and is not known to contain infectious hepatitis virus.
Laboratory data have shown that the lyophilized vaccine containing 2% HSA is highly resistant to thermal deterioration and extremely stable in its immunogenic potency. These characteristics make stockpiling and shipment of the vaccine unrefrigerated entirely feasible, and permit the use of this product as a reference vaccine.
Footnotes
1 A preliminary report on these findings was presented at a Symposium on Immunization against Arbovirus Infections held at the Eleventh Annual Meeting of the American Society of Tropical Medicine and Hygiene, Atlanta, Georgia, November 2, 1962 (3).
This article has been cited by other articles:
![]() |
J. D. Grabenstein, P. R. Pittman, J. T. Greenwood, and R. J.M. Engler Immunization to Protect the US Armed Forces: Heritage, Current Practice, and Prospects Epidemiol. Rev., August 1, 2006; 28(1): 3 - 26. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |